-

11:49:06 AM

BCDA Stock News

BCDA - BioCardia Inc.

05/11/22 4:15 PM

Nasdaq : BCDA

earningslow float

BioCardia Reports First Quarter 2022 Business Highlights and Financial Results

BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2022 and filed its quarterly report on

RHEA-AI

neutral

05/04/22 8:30 AM

Nasdaq : BCDA

conferencesearningslow float

BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022

BioCardia ®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three months ended March 31, 2022 and

RHEA-AI

neutral

04/12/22 7:15 AM

Nasdaq : BCDA

fda approvalcovid-19low float

BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19

BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug

RHEA-AI

neutral

03/29/22 4:05 PM

Nasdaq : BCDA

earningslow float

BioCardia Reports 2021 Financial Results and Recent Business Highlights

BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2021 and filed its annual

RHEA-AI

neutral

03/24/22 8:00 AM

Nasdaq : BCDA

conferencesearningslow float

BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022

BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2021 and

RHEA-AI

neutral

03/22/22 8:30 AM

Nasdaq : BCDA

low float

BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure

BioCardia®, Inc.

RHEA-AI

neutral

03/01/22 8:00 AM

Nasdaq : BCDA

low float

BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada

BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, the country’s

RHEA-AI

neutral

02/14/22 7:30 AM

Nasdaq : BCDA

low float

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its

RHEA-AI

neutral

02/03/22 8:00 AM

Nasdaq : BCDA

low float

BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure

BioCardia ®, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for the CardiAMP ® Cell Therapy System for the treatment of heart failure. It is believed to be the first cardiac cell...

RHEA-AI

positive

01/10/22 8:00 AM

Nasdaq : BCDA

low float

BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference

BioCardia ®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and respiratory diseases, today announced it will be delivering virtual presentations during two

RHEA-AI

neutral

BCDA Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.biocardia.com
CeoPeter Altman
Security nameBioCardia Inc.
Issue typecs
SectorManufacturing
Sic code3842
Employees27
Tags
- Biotechnology
- Health Technology
- Manufacturing
- Surgical and Medical Instrument Manufacturing
Address125 Shoreway Rd Ste B
StateCalifornia
CitySan Carlos
Zip94070-2718
CountryUS
Phone16502260120

About BioCardia Inc.

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction.